Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2012-12-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138955713804484802PMID 23256485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites

  2011cited by this paper
• Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

  2011cited by this paper
• Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors

  2011cited by this paper
• Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis.

  2011cited by this paper
• Candida and invasive candidiasis: back to basics

  2011cited by this paper
• Candida albicans, a major human fungal pathogen

  2011cited by this paper
• HIV aspartyl protease inhibitors as promising compounds against Candida albicans

  2010cited by this paper
• Aspartic Peptidase Inhibitors as Potential Bioactive Pharmacological Compounds Against Human Fungal Pathogens

  2010cited by this paper
• Oropharyngeal candidiasis in the era of antiretroviral therapy.

  2010cited by this paper
• Invasive Fungal Infections in the ICU

  2010cited by this paper
• HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces

  2010cited by this paper
• Antifungal drug resistance of oral fungi

  2010cited by this paper
• Multiple effects of amprenavir against Candida albicans.

  2010cited by this paper
• Identifying infection-associated genes of Candida albicans in the postgenomic era.

  2009cited by this paper
• Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review

  2009cited by this paper
• Epidemiology of invasive fungal infection.

  2008cited by this paper
• Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act.

  2008cited by this paper
• Different domains of the UBL-UBA ubiquitin receptor, Ddi1/Vsm1, are involved in its multiple cellular roles.

  2008cited by this paper
• Tipranavir exhibits different effects on opportunistic pathogenic fungi.

  2008cited by this paper
• Changing epidemiology of systemic fungal infections.

  2008cited by this paper
• Design of Potent Aspartic Protease Inhibitors to Treat Various Diseases

  2008cited by this paper
• Niche-specific gene expression during C. albicans infection.

  2008cited by this paper
• Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

  2007cited by this paper
• Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells

  2007cited by this paper
• Morphogenesis in Candida albicans.

  2007cited by this paper
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

  2007cited by this paper
• Ddi1, a eukaryotic protein with the retroviral protease fold.

  2006cited by this paper
• Candida-Host Interactions in HIV Disease: Relationships in Oropharyngeal Candidiasis

  2006cited by this paper
• Invasive Fungal Pathogens: Current Epidemiological Trends

  2006cited by this paper
• Secretion of serine peptidase by a clinical strain of Candida albicans: influence of growth conditions and cleavage of human serum proteins and extracellular matrix components.

  2006cited by this paper
• Contributions of hyphae and hypha‐co‐regulated genes to Candida albicans virulence

  2005cited by this paper
• Candida, still number one – what do we know and where are we going from there?

  2005cited by this paper
• Hydrolytic enzymes as virulence factors of Candida albicans

  2005cited by this paper
• An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART

  2005cited by this paper
• Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strains.

  2004cited by this paper
• Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

  2004cited by this paper
• Candida albicans proteinases and host/pathogen interactions

  2004cited by this paper
• Social support and quality of life over time among adults living with HIV in the HAART era.

  2004cited by this paper
• Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.

  2003cited by this paper
• Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient.

  2003cited by this paper
• Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

  2003cited by this paper
• A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

  2003cited by this paper
• Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis

  2003cited by this paper
• Aspartic Peptidase Inhibitors: Implications in Drug Development

  2003cited by this paper
• Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.

  2002cited by this paper
• Candida commensalism and virulence: the evolution of phenotypic plasticity.

  2002cited by this paper
• Adhesion in Candida spp

  2002cited by this paper
• Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.

  2002cited by this paper
• Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

  2002cited by this paper
• NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM H. SECULAR TREND OF HOSPITAL-ACQUIRED CANDIDEMIA AMONG INTENSIVE CARE UNIT PATIENTS IN THE UNITED STATES DURING 1989-1999

  2002cited by this paper
• HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.

  2001cited by this paper
• Aspartyl proteinases of Candida albicans and their role in pathogenicity.

  2001cited by this paper
• Chronic vulvovaginal candidiasis.

  2001cited by this paper
• The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals.

  2001cited by this paper
• Candida albicans proteinases: resolving the mystery of a gene family.

  2001cited by this paper
• Virulence factors of Candida albicans.

  2001cited by this paper
• Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

  2001cited by this paper
• Candida proteases and their inhibition: prospects for antifungal therapy.

  2001cited by this paper
• Fungal morphogenesis and virulence.

  2000cited by this paper
• Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel

  2000cited by this paper
• Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.

  2000cited by this paper
• Potential role of phospholipases in virulence and fungal pathogenesis.

  2000cited by this paper
• Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy.

  1999cited by this paper
• Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.

  1999influential reference
• In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.

  1999cited by this paper
• Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients.

  1999cited by this paper
• Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.

  1999cited by this paper
• Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of Candida albicans Isolates from HIV-Infected Patients

  1999cited by this paper
• HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases.

  1999cited by this paper
• The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages

  1998cited by this paper
• HIV-protease inhibitors.

  1998cited by this paper
• [Immunopathogenesis of recurrent vulvovaginal candidiasis].

  1996cited by this paper
• Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents

  1996cited by this paper
• Immunopathogenesis of recurrent vulvovaginal candidiasis

  1996cited by this paper
• Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.

  1994cited by this paper
• Treatment of oral candidiasis in HIV infection.

  1994cited by this paper
• Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

  1994cited by this paper
• Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor

  1987cited by this paper
• Proteolysis and pathogenicity of Candida albicans strains

  1969cited by this paper

• A small heat shock protein Fmp28 influences virulence by regulating Als3 expression via the cAMP-PKA signaling pathway in Candida albicans

  2025cites this paper
• Imidazolidine‐Based Aspartate Inhibitors for Candida Infections

  2025cites this paper
• In-vitro Evaluation of the Antifungal Property of Cold-Pressed Coconut oil Against Drug-Resistant Candida albicans and in-Silico Bioactivity Against Candidapepsin-2

  2024cites this paper
• Anticandidal Effect of New Imidazole Derivatives Over Aspartic Protease Inhibition

  2024cites this paper
• Saps1–3 Antigens in Candida albicans: Differential Modulation Following Exposure to Soluble Proteins, Mammalian Cells, and Infection in Mice

  2024cites this paper
• Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in Cryptococcus neoformans

  2024cites this paper
• Plasma activated Ezhangfeng Cuji as innovative antifungal agent and its inactivation mechanism

  2023cites this paper
• β-Nitrostyrene derivatives as broad range potential antifungal agents targeting fungal cell wall.

  2022cites this paper
• Characterization of Defensin-like Protein 1 for Its Anti-Biofilm and Anti-Virulence Properties for the Development of Novel Antifungal Drug against Candida auris

  2022cites this paper
• From Naturally-Sourced Protease Inhibitors to New Treatments for Fungal Infections

  2021cites this paper
• Synthesis, molecular docking, and in silico ADME prediction of some fused pyrazolo[1,5-a]pyrimidine and pyrazole derivatives as potential antimicrobial agents

  2021cites this paper
• Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery

  2021cites this paper
• Anti-inflammatory potential of myristic acid and palmitic acid synergism against systemic candidiasis in Danio rerio (Zebrafish).

  2021cites this paper
• Bioguided isolation, identification and activity evaluation of antifungal compounds from Acorus tatarinowii Schott.

  2020cites this paper
• In vitro activities of Traganum nudatum and Mentha pulegium extracts combined with amphotericin B against Candida albicans in production of hydrolytic enzymes

  2020cites this paper
• Increments in virulence of Candida albicans induced by androgenic anabolic steroids.

  2019cites this paper
• The serine peptidase inhibitor TPCK induces several morphophysiological changes in the opportunistic fungal pathogen Candida parapsilosis sensu stricto.

  2019cites this paper
• Molecular Docking Analysis of Bioactive Compounds of Acacia Concinna against Fungal Protein

  2019cites this paper
• Effets de la dermaseptine-S 1 sur la croissance, la transformation, la formation de biofilms et l'expression de certains gènes de virulence de C. albicans

  2018cites this paper
• Antifungal, antibiofilm, and antiproliferative activities of Guapira graciliflora Mart.

  2018cites this paper
• Fonsecaea pedrosoi Sclerotic Cells: Secretion of Aspartic-Type Peptidase and Susceptibility to Peptidase Inhibitors

  2018cites this paper
• Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections.

  2018cites this paper
• Anticancer Drugs as Antibiofilm Agents in Candida albicans: Potential Targets

  2018cites this paper
• Dermaseptin‐S1 decreases Candida albicans growth, biofilm formation and the expression of hyphal wall protein 1 and aspartic protease genes

  2018cites this paper
• Molecular Targets for Anticandidal Chemotherapy

  2017cites this paper
• HIV Aspartic Peptidase Inhibitors Modulate Surface Molecules and Enzyme Activities Involved with Physiopathological Events in Fonsecaea pedrosoi

  2017influential citation
• The HIV aspartyl protease inhibitor ritonavir impairs planktonic growth, biofilm formation and proteolytic activity in Trichosporon spp.

  2017cites this paper
• Roles of Candida albicans aspartic proteases in host-pathogen interactions

  2017cites this paper
• Fatores de Virulência de Candida albicans Isoladas da Mucosa Oral de Pacientes HIV Positivo

  2017cites this paper
• 7-hydroxycalamenene Effects on Secreted Aspartic Proteases Activity and Biofilm Formation of Candida spp.

  2016cites this paper
• Review of the current status and future perspectives on Pseudogymnoascus destructans studies with reference to the species findings in Bulgaria

  2016cites this paper
• Anti-candida and anti-enzyme activity and cytotoxicity of 2-phenyl-4H-chromen-4-one

  2016cites this paper
• Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches

  2016cites this paper
• Protease Inhibitors as Ad-hoc Antibiotics

  2016cites this paper
• Inactivation of α1-proteinase inhibitor by Candida albicans aspartic proteases favors the epithelial and endothelial cell colonization in the presence of neutrophil extracellular traps.

  2016cites this paper
• Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro

  2015cites this paper
• Predisposing factors endorsing Candida infections.

  2015cites this paper
• Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome

  2015cites this paper
• Differential Expression of Extracellular Lipase and Protease Activities of Mycelial and Yeast Forms in Malassezia furfur

  2015cites this paper
• Comparative genomic analysis of aspartic proteases in eight parasitic platyhelminths: insights into functions and evolution.

  2015cites this paper
• Genome-wide analysis of regulatory proteases sequences identified through bioinformatics data mining in Taenia solium

  2014cites this paper
• Prevalência de Candida spp. na saliva de crianças com leucemia e a influência da lactoferrina na expressão de genes relacionados com a formação de biofilme

  2014cites this paper
• Aspartic Proteolytic Inhibitors Induce Cellular and Biochemical Alterations in Fungal Cells

  2013cites this paper